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Abstract
Background: Benign prostatic enlargement is the most 
common benign disease in men. The main cause for the 
emergence of benign prostatic enlargement is sexual 
hormone testosterone. Under the influence of enzyme 
5-alpha reductase testosterone turns into active dihy-
drotestosterone, which is then combined with recep-
tors and causes the growth of the prostate. Benign 
prostatic enlargement can cause the lower urinary tract 
symptoms. One of the treatment options of lower uri-
nary tract symptoms due to benign prostatic enlarge-
ment is the treatment with medicaments – inhibitors 
5-alpha reductase. Like any other medicament, this one 
can also have unpleasant side effects, between others 
reduced erectile function and reduced libido. 
Methods: We used the International Index of Erectile 
Function (IIEF-5), Quality of Erection Questionnaire (QEQ), 
and demographic data. 
Results: Men with benign prostatic enlargement have 
problems with keeping an erection even before starting 
the therapy with medicaments. After the therapy with 
inhibitors 5-alpha reductase the results of the research 
show that on the erectile function scale, there are no 
significant differences between the first and second 
measurement, but on the erectile dysfunction scale ex-
pected differences occur – the functionality decreases. 
We also noticed that the independent variables of age 
and employment status have influence on the result of 
medicament treatment in the way that older partici-
pants in the study have more issues with erectile func-
tion than younger ones. Secondly, the men in retirement 
have more problem than employed men. There were no 
noticeable connections between the level of completed 
education and the profession of the participants. 
Conclusions: The results of the research were expected, 
according to the previously consulted literature, where the 
side effects of treatment with medicaments inhibitors 5-al-
pha reductase were already mentioned. The effects that 
the treatment has on erectile function are that the function 
deteriorates, that is why it is important that we seek doctor 
assistance immediately after it occurs. The disease mainly 
manifests itself in older generation of men and it has a neg-
ative effect on erectile function already at the very begin-
ning. Before starting the treatment the patients would need 
to be informed about the side effects of the medicament 
treatment and they should be presented other possibili-
ties of treatment without side effects for erectile function.
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the problems are mild, then treatment with medication 
should be started. When the problems do not cease 
even after medication and cause even more complica-
tions (bleeding, halting of urination, etc.) then the doc-
tor will consider surgical treatment.
For the treatment of LUTS caused by BPE, 5-alpha re-
ductase inhibitors (5ARI), inhibitors α-1-adrenergic 
blockers (inhibitors α 1 AR), muscarinic receptor an-
tagonist (MRA), β3 (beta 3) adrenergic receptor agonist, 
herbal medications, or different combinations of drugs 
are used. Finasteride and dutasteride are parts of 5-al-
pha reductase inhibitors, and tamsoluzine is a part of 
α-1-adrenergic blockers inhibitors8. The type of medica-
tion prescribed depends on the prostate volume. If the 
measured volume is between 25 and 40 cm³, the doctor 
will prescribe α-1-adrenergic inhibitors, and if the vol-
ume is above 40 cm³, then 5-alpha reductase inhibitors 
will be prescribed.
5-alpha reductase inhibitors are medications that af-
fect the 5-alpha reductase enzyme. 5-alpha reductase 
changes testosterone into dihydrotestosterone, and if 
this process is impeded, then there is not enough dihy-
drotestosterone, which would make the prostate tis-
sue grow. This medication decreases the volume of the 
prostate by 20-30%, and the effect is seen after some 
time of therapy. The bigger the prostate is, the more ef-
fective this medication is. The effect of the drug can al-
so be seen in lower concentrations of PSA in the blood. 
After 6 to 12 months of treatment, PSA in the blood is 
reduced by half,8. 
Kirk states that this type of therapy is safe and has 
minimal side effects9. Nevertheless, a few men mention 
erectile problems and other problems connected to li-
bido. In most cases, when the therapy is stopped, the 
problems vanish. 
Hoffman4 determined that these medications can have 
a side effect of the enlargement of breast tissue (gyne-
comastia). McVary and his colleagues10 observed the 
treatment with finasterides or combination therapy 
may lead to a decreased sexual desire and can cause 
worse erectile and ejaculation functions. Similar results 
are also found by Fwu and his team11, who state that 
both options of therapy lead to lower erectile function.
Erectile dysfunction (ED) or disruption of erection is the 
inability to get and hold an erection for satisfying sexual 
intercourse12.
Introduction 
The prostate is a secondary male sexual organ situated 
between the bladder neck and outer sphincter muscle. 
The volume of the gland is approximately 25 cm³. Its 
main tasks are to produce a secretion, which is a part 
of the sperm liquid, and to store zinc (Zn). Zinc plays an 
antibacterial role and protects the prostate against in-
flammation. The prostate also significantly influences 
the quality of life of men in maturity and old age1,2,3. In 
the process of ageing, the gland in the transitional zone 
grows by cell multiplication, which is why an adenoma 
grows and pushes the normal tissue to the edge of the 
prostate. The sexual hormone testosterone plays the 
primary role in this process. In the prostate, testosterone 
under the influence of 5-alpha reductase transfers to di-
hydrotestosterone, which then connects with receptors4. 
Benign prostatic enlargement (BPE) is a medical term 
for prostate growth in old age. BPE is the most common 
disease in men and can cause lower urinary tract symp-
toms (LUTS). Although it is usually not a fatal disease, its 
symptoms can severely worsen the quality of a patient’s 
life1. Tatt Foo5 describes BPE as a medical condition in 
which the abnormal enlargement of the gland at differ-
ent levels of intensity can harm the bladder or kidneys, 
because it disrupts the flow of urine.
In his research, Lim6 mentions a strong correlation be-
tween the disease, genetics, and unhealthy lifestyle 
(poor nutrition, lack of sport activities). The same risk 
factors for the emergence of BPE are mentioned in the 
work of Parsons7. He mostly connects BPE with age and 
genetic factors. 
Patients with BPE can show lower urinary tract symp-
toms or no symptoms at all. If BPE starts to squeeze the 
urethra and move the side tissue, then it starts causing 
problems. It often happens that the enlarged prostate 
spreads away from the urethra area and it does not 
cause squeezing, which is why the patient shows no 
symptoms, even though the prostate has enlarged sig-
nificantly. When the patient notices symptoms of the 
lower urinary tract, he needs to seek proper treatment4. 
Trsinar divides the treatment according to the prob-
lems caused by urinating1. If the patient has mild prob-
lems because of BPE, doctors only need to monitor the 
situation, make regular checks and suggest general pre-
ventive measures according to the patient’s lifestyle. If 
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confirm the second hypothesis, we used a parametric 
regression test, because we observed a linear connec-
tion between two of the variables (i.e., age and em-
ployment status). With the help of regression, we also 
described the influence of these two variables on each 
other. 
Results
Fifty individuals participated in the first part of the 
study. They all differed in age, education level, employ-
ment status, and profession. The sample consisted 
solely of male participants. The majority of the sample 
(n = 18; 36%) was aged between 58 and 63 years and 
between 64 and 69 years (n = 18; 36%). There were few 
participants older than 70 years n (= 12; 24%), and the 
fewest (n = 2; 4%) were between 52 and 57 years old. 
There were no participants less than 52 years old. 
The participants also differed in education level. The 
majority had completed secondary school education 
(n = 24; 48%). The same number of participants (n = 8; 
16%) had completed primary school education and ter-
tiary education. A part of the participants did not com-
plete high school (n = 4; 8%), the same percentages did 
not complete primary or higher education (n = 3; 6%).
The common average result of the IIEF-5 scale showed 
that the individuals had mild to moderate erectile 
dysfunction on average at the first measurement. The 
second measurement showed that the individuals on 
Methodology
For this study, we used the International Index of Erec-
tile Function (IIEF-5), the Quality of Erection Question-
naire (QEQ), and demographic data from the partici-
pants. The study was held in General Hospital Celje, in 
the urology department, in Slovenia. The study consists 
of two parts. The first part was from November 2017 
to February 2018, in which time a questionnaire was 
given to the patients on their urology examination, with 
which we wanted to evaluate the state of their erectile 
function before starting the treatment with medication. 
The second part of the study was from May 2018 to Au-
gust 2018, in which time the same questionnaire was 
given to the patients who came for an examination, af-
ter the start of the treatment. Fifty persons were invited 
to the study; all of them received the questionnaires. 
First, the data were analysed with Microsoft Office Ex-
cel 2010. The nominal and ordinal variables were de-
termined. After that, we used descriptive statistics and 
analysed the data with SPSS 22.0. We complied with 
statistical attribute at the value p < 0, 05.
After the first measurement of the entire sample, the 
distribution of both scales differed from normal distri-
bution. On the scale of the repeated sample at the first 
and second measurements, only the QEQ scale differed 
from normal. We can also observe flatness from the 
asymmetric coefficients, as well as from the Kolmogo-
rov-Smirnov test, which is not statistically typical. Be-
cause of the size of the sample and the abnormality of 
the data distribution, we will use non-parametric tests 
in continuation for testing our hypothesis (Table 1). To 
Table 1. Descriptive statistics and normal distribution of scales IIEF-5 and QEQ 
asymmetry Flatness Kolmogorov-Smirnov
n M SD As Se Spl Se p
1. measurement
IIEF-5 50 13.98 7.19 -0.77 0.34 -0.30 0.66 0.03*
QEQ 50 42.83 32.73 -0.05 0.34 -1.41 0.66 0.01*
2. measurement
IIEF-5 31 11.58 7.21 -0.01 0.42 -0.86 0.82 0.20
QEQ 31 34.54 32.88 0.39 0.42 -1.04 0.82 0.00*
Legend: n – amount of surveys; M – arithmetical middle; SD – standard deviation; As – coefficient of asymmetry; Se – standard coefficient 
mistake; Spl – coefficient of flatness; p – the importance of normal distribution coefficient
remarks: *p < 0,05
80 Štraus A. et al. The Effect of Therapy of the Lower Urinary Tract Symptoms due to Prostatic Benign Enlargement... J. appl. health sci. 2020; 6(1): 77-82
no significant differences between the first and second 
measurements.
Men with BPE had problems keeping an erection prior 
to starting the treatment with medications. After the 
treatment, there were no significant differences be-
tween measurements on the quality scale. However, 
there were noticeable differences on the scale of erec-
tile dysfunction: functionality decreased severely.
The second hypothesis states that age, education level, 
profession, and employment status do not affect the 
outcome of treatment (5-alpha reductase inhibitors) of 
LUTS caused by BPE. First, we verified whether the in-
dependent variables have connections with the results 
of the first or second measurements, so that we could 
research the possible influence of individual variable.
Calculating the connectedness, we discovered that 
age has a significant connection with the results of the 
IIEF-5 scale (r = –0.48), and with results of the QEQ scale 
(r = –0.38). The connection is negative, which means 
that individuals in older age group have lower results 
on both scales, which indicates worse erectile function 
at older patients. Other variables do not have signifi-
cant connections with either of the scales.
At the second measurement, there are significant con-
nections with results on the scales in the areas of age 
and employment status. The results were expected, be-
cause they again show that older patients have more 
problems with erections. At the same time, pensioners 
are reporting these issues more than employed indi-
viduals are. 
As the therapy with medication showed some significant 
connections between erectile dysfunction, age and em-
ployment status, we checked, using regression, if these 
variables have some influence on the result itself. 
Using multiple regression analysis, we checked if the 
demographic variables (age, education level, employ-
ment) had an impact on the result of the treatment of 
LUTS caused by BPE. The results of regression showed 
that 32% of variance IIEF-5 test with demographical 
variables in which the predictor of employment status 
showed as statistically significant. In the case of the 
QEQ questionnaire, we can explain 29% of the result 
variance with demographic variables, which also con-
firms the statistical importance of employment status. 
Based on employment status (employed or pensioner), 
we can predict the outcome of questionnaires IIEF-5 
and QEQ, which show that pensioners are expected to 
have more problems.
average had moderate erectile dysfunction. The joint 
average result from QEQ scale showed that the quality 
of erection is better at first measurement in comparison 
to the second one, because the result is better on the 
scale from 0 to 100. Next, we checked if the differences 
were statistically significant.
On the level of the entire sample, the distributions of 
both scales deviate from normal at the first measure-
ment. On the level of the repeated sample, at the first 
and second measurements only, the QEQ scale devi-
ates from normality. We also observed that in the coef-
ficients of asymmetry and flatness and in the Kolmogo-
rov-Smirnov test, which was not statistically common. 
Because of the size of the sample and abnormality in 
the distribution of data, we used nonparametric tests 
for confirming the hypothesis. 
Discussion
In the first part of the study, we had 50 participants. 
They all differed in age, education level, employment 
status, and profession. We only had male participants 
in the sample. The second part of the study consisted of 
31 participants. All of them were a part of the first part. 
The hypothesis: Men with LUTS caused by BPE have 
problems with erection prior to starting treatment 
with 5-alpha reductase inhibitors. After the treatment, 
erectile function worsens. The hypothesis showed that 
there are significant changes on the IIEF-5 scale; how-
ever, there are no statistically significant changes in the 
results on the QEQ scale. The results show that, based 
on the IIEF-5 questionnaire, the individuals have mild 
erectile dysfunction on average before starting the 
treatment with medication. This statement confirms 
our first hypothesis. 
The expected result was that men with BPE had prob-
lems with keeping an erection before starting therapy 
with medication. We discovered that in the case of 
the IIEF-5 scale, with which we evaluated erectile dys-
function, there are noticeable differences between the 
first and second measurements. The patients claim 
even worse erectile function at the time of the second 
measurement. Based on the questionnaire QEQ, which 
measured the quality of erectile function, there were 
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Conclusions and recommendations
The prostate is a very important organ in every man. It 
carries out multiple tasks and it is indispensable for var-
ious processes in the life of the individual13. In cases of 
diseases of the organ, medical treatment is inevitable. 
The doctor will then decide on the treatment, either 
with medication, operation or a combination of both. 
One common disease in older men is benign enlarged 
prostate, which can affect other organs and cause prob-
lems or medical conditions, such as lower urinary tract 
symptoms. Erectile dysfunction can also occur, which 
not only worsens the physical but also the psychologi-
cal health of a patient14,15. 
With analysis, we discovered that therapy with 5-alpha 
reductase inhibitors for healing LUTS caused by BPE af-
fects erectile function. We also confirmed the hypothesis 
and answered the research questions. Even though the 
results were anticipated, we think they can be used in 
practice. The patients who are prescribed therapy with 
medication need to be informed about the risks. Opin-
ions and research about this topic have previously ap-
peared in the literature, also mentioning unwanted side 
effects, which demonstrate the significance of informa-
tion for the patients. They need to be presented with the 
process of treatment and other therapy possibilities. 
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Sažetak
Uvod: Dobroćudno povećanje prostate je najčešća do-
broćudna bolest u muškaraca. Glavni uzročnik pojave 
dobroćudnog povećanja prostate je muški spolni hor-
mon testosteron. Pod utjecajem enzima 5-alfa redukta-
ze testosteron se pretvara u aktivni dihidrotestosteron, 
koji se tada kombinira s receptorima i uzrokuje rast pro-
state. Dobroćudno povećanje prostate može uzrokova-
ti simptome u donjem mokraćnom sustavu. Jedna od 
mogućnosti liječenja simptoma donjeg dijela mokrać-
nog sustava uslijed dobroćudnog povećanja prostate 
je liječenje lijekovima - inhibitorima 5-alfa reduktaze. 
Kao i bilo koji drugi lijek, i ovaj može imati neugodne 
nuspojave, između ostalih smanjenu erektilnu funkciju 
i smanjeni libido.
Metode: Koristili smo međunarodni indeks erektilne 
funkcije (IIEF-5), upitnik o kvaliteti erekcije (QEQ) i de-
mografske podatke.
Rezultati: Muškarci s benignim povećanjem prostate 
imaju problema s održavanjem erekcije, čak i prije nego 
što započnu terapiju lijekovima. Nakon terapije inhibi-
torom 5-alfa reduktaze rezultati istraživanja pokazuju 
da na ljestvici erektilne funkcije nema značajnih razlika 
između prvog i drugog mjerenja, ali na ljestvici erektil-
ne disfunkcije dolazi do očekivanih razlika - funkcional-
nost opada. Također smo primijetili da nezavisne varija-
ble dobi i zaposlenja imaju utjecaj na rezultat liječenja 
lijekovima na način da stariji sudionici u istraživanju 
imaju više problema s erektilnom funkcijom od mlađih 
muškaraca. Zatim, muškarci u mirovini imaju više pro-
UTJECAJ LIJEČENJA SIMPTOMA DONJEG MOKRAĆNOG SUSTAVA 
UZROKOVANIH DOBROĆUDNIM POVEĆANJEM PROSTATE NA EREKTILNU 
FUNKCIJU
blema nego muškarci koji su zaposleni. Nisu bile uočlji-
ve veze između završene razine obrazovanja i profesije 
sudionika.
Zaključci: Rezultati istraživanja bili su očekivani, prema 
prethodno konzultiranoj literaturi, gdje su već spome-
nute nuspojave liječenja inhibitorima 5-alfa reduktaze. 
Učinak koji tretman ima na erektilnu funkciju je pogor-
šanje funkcije, zato je važno potražiti pomoć liječnika 
odmah nakon što se pojavi. Bolest se uglavnom očituje 
kod starije generacije muškaraca i negativno utječe na 
erektilnu funkciju već u samom početku. Prije početka 
liječenja, pacijente bi trebalo informirati o nuspojava-
ma liječenja lijekovima i treba im predstaviti druge mo-
gućnosti liječenja bez nuspojava za erektilnu funkciju. 
Ključne riječi: benigna proširenja prostate, erektilna funkcija, 
liječenje lijekovima, simptomi donjeg mokraćnog sustava
